NCI, US TOO Form Educational Partnership

Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

BETHESDA, Md--It's called "Know Your Options: The National Prostate Cancer Education Program," and it's a joint effort by the National Cancer Institute and US TOO International, the world's largest men's cancer group.

BETHESDA, Md--It's called "Know Your Options: The National ProstateCancer Education Program," and it's a joint effort by the NationalCancer Institute and US TOO International, the world's largest men's cancergroup.

The two organizations have taken aim at men age 50 and older, and those40 or over who are at high risk of prostate cancer, to increase their awarenessabout the detection, diagnosis, and management of the disease.

The effort will include multicity symposia for health professionalsand lay audiences, the development of interactive software to provide informationabout prostate cancer, and enhancement of US TOO's website (http://www.ustoo.com)to help men sort through the complexities of prostate cancer management.

Related Videos
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Expert cardiologist
Expert urologist
Expert cardiologist
Expert urologist
Expert urologist
Expert urologist
Expert oncologist
Related Content